Laddar...
Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data
Dulaglutide is a once-weekly glucagon-like peptide-1 receptor agonist, which has been on the market in the USA since 2014. Dulaglutide has performed well in head-to-head studies against metformin, glargine, and sitagliptin, where its A1c lowering ranged from −0.78% to −1.64% over 52–104 weeks, and i...
Sparad:
| I publikationen: | Diabetes Metab Syndr Obes |
|---|---|
| Huvudupphovsmän: | , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Dove Medical Press
2018
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5951211/ https://ncbi.nlm.nih.gov/pubmed/29780260 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S134960 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|